Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\nQUÉBEC CITY, Feb. 3, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced that presentations on\n two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and\n disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.\n\n\nThe session will be held on Tuesday, February 11, 2014, in Hall A of the\n Wyndham Hotel in Salzburg.\nPresentations are scheduled as follows:\n\n\n\n\n\n\n10:30 am\n\n\n\"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: Overview\n of Clinical Results\"\n\n\n\n\n \n\n\nSpeaker: Dr. Günter Emons, Chairman, Department of Obstetrics &\n Gynaecology, Georg-August University Göttingen, Germany\n\n\n\n\n \n\n\n \n\n\n\n\n11:00 am\n\n\n\"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: GnRH\n Receptor Targeting in Triple-Negative Breast Cancer\"\n\n\n\n\n \n\n\nSpeaker: Dr. Jörg B. Engel, Medical University of Regensburg, Department\n of Gynaecology and Obstetrics, Germany\n\n\n\n\n \n\n\n \n\n\n\n\n11:15 am\n\n\n\"New and Highly Potent Disorazol Z GnRH Conjugates: Concept and Mode of\n Action\"\n\n\n\n\n \n\n\nSpeaker: Dr. Babette Aicher, Director, Preclinical Development, Aeterna\n Zentaris\n\n\n\n\n \n\n\n \n\n\n\n\n11:45 am\n\n\n\"New and Highly Potent Disorazol Z GnRH Conjugates: Preclinical Results\n in Endometrial Cancers\"\n\n\n\n\n \n\n\nSpeaker: Dr. Carsten Gruendker, Department of Obstetrics & Gynaecology,\n Georg-August University Göttingen, Germany\n\n\n\n\n\n\n\nAbout Aeterna Zentaris Inc.\n\n\nAeterna Zentaris is a specialty biopharmaceutical company engaged in\n developing novel treatments in oncology and endocrinology. The\n Company's pipeline encompasses compounds from drug discovery to\n regulatory approval. For more information, visit www.aezsinc.com.\n\n\nForward-Looking Statements\n\n\nThis press release contains forward-looking statements made pursuant to\n the safe harbour provisions of the U.S. Securities Litigation Reform\n Act of 1995. Forward-looking statements involve known and unknown risks\n and uncertainties that could cause the Company's actual results to\n differ materially from those in the forward-looking statements. Such\n risks and uncertainti...

More updates from Cosciens Biopharma Inc.